.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
Fish and Richardson
QuintilesIMS
McKesson
Moodys
Healthtrust
Cerilliant
Deloitte
Covington

Generated: July 26, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
Abstract:Human growth hormone variants are disclosed wherein the lysine at position 41 and/or the leucine at position 45 of native human growth hormone, numbered from the mature N-terminus of native human growth hormone, has been replaced with another amino acid. Also claimed are combination variants that have a higher binding affinity to the growth hormone receptor than wild-type human growth hormone.
Inventor(s): Cunningham; Brian C. (Piedmont, CA), Lowman; Henry (Hercules, CA), Wells; James A. (Burlingame, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Filing Date:May 25, 1993
Application Number:08/067,160
Claims:1. A human growth hormone variant having at least one amino acid substitution selected from the group consisting of the lysine at position 41 and the leucine at position 45 of native human growth hormone, numbered from the mature N-terminus of native human growth hormone.

2. The variant of claim 1 wherein the variant has at least one amino acid substitution selected from the group consisting of K41I, K41R, and L45W.

3. A human growth hormone variant having at least two amino acid residues replaced with different amino acid residues, wherein the variant has a set of amino acid substitutions selected from the group consisting of F54P,E56D, I58T,R64K; F54P,E56W,I58T,R64K; and F54P,R64K, numbered from the mature N-terminus of 191-amino acid human growth hormone.

4. A composition comprising a human growth hormone variant having at least one amino acid substitution selected from the group consisting of the lysine at position 41 and the leucine at position 45 of native human growth hormone, numbered from the mature N-terminus of native human growth hormone and a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Dow
Cantor Fitzgerald
Baxter
Citi
Cipla
Chinese Patent Office
Fuji
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot